US FDA Officials Offer Tips On How To Improve CMC Packages To Win Generic Approvals
This article was originally published in SRA
With the US Food and Drug Administration increasingly refusing to receive generic drug applications (also called abbreviated new drug applications or ANDAs) typically because of deficiencies relating to chemistry, manufacturing and controls (CMC), agency officials recently shared some advice on how sponsors can improve their submissions on this front.
You may also be interested in...
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.